Reuters Health Information: Kidney transplant success varies with HIV and HCV co-infection
Kidney transplant success varies with HIV and HCV co-infection
Last Updated: 2015-03-24
By David Douglas
NEW YORK (Reuters Health) - HIV-positive patients not
co-infected with hepatitis C virus (HCV) show long-term kidney
transplant survival comparable to that of HIV-negative
recipients.
"To date, this is the first national study examining
long-term outcomes among the entire U.S. cohort of HIV-positive
kidney transplant recipients. Our study demonstrates similar
five- and 10-year post-transplant survival among monoinfected
HIV-positive and uninfected HIV-negative recipients," Dr. Jayme
E. Locke, of the University of Alabama at Birmingham, told
Reuters Health by email.
In a March 19 online paper in the Journal of the American
Society of Nephrology, Dr. Locke and colleagues note that kidney
transplantation is now offered as a treatment option for
HIV-positive patients with end-stage kidney disease.
The team examined data on 510 HIV-positive patients who
underwent first-time kidney transplantation between 2002 and
2011. They were matched 1:10 with HIV-negative recipients.
Median follow-up was 3.8 years in the HIV-positive group.
Overall, five- and 10-year graft survival rates were
significantly lower in the HIV-positive group compared with the
HIV-negative group (69.2% vs. 75.3% at five years and 49.8% vs.
54.4% at 10 years, p=0.003 and p<0.001).
However, when limited to HIV-negative/HCV-negative
patients, mono-infected HIV-positive recipients had similar
five-year and 10-year graft survival rates compared with
uninfected recipients (75.0% vs. 75.8% at five years and 55.9%
vs. 56.0% at 10 years).
Recipients who were HIV-positive and HCV-positive had a 52%
graft survival at five years and 27% survival at 10 years,
compared with HIV-negative/HCV-positive patients, who had 64.0%
survival at five years and 36.2% survival at 10 years (p=0.01).
HIV-positive patients had similar five-year patient
survival rates compared with HIV-negative patients (83.5% vs.
86.2%) but significantly lower 10-year rates (51.6% vs. 72.1%,
p<0.01).
"These results are encouraging," the investigators
conclude, "but do suggest caution in transplanting HIV-positive
recipients co-infected with HCV, motivating future studies of
survival benefit."
Dr. Locke added, "Understanding long-term outcomes among
HIV-positive kidney transplant recipients is paramount to ensure
continued access to life-saving kidney transplantation in this
vulnerable population."
In an accompanying editorial, Drs. Alissa J. Wright, of the
University of British Columbia, Vancouver, and John S. Gill, of
Tufts-New England Medical Center, Boston, write that the authors
"should be commended for providing a national perspective."
Dr. Wright told Reuters Health by email "This study
demonstrates the excellent real-world outcomes that can be
achieved in patients with HIV infection who undergo renal
transplantation. However, it also highlights the acute need for
different ways to study this topic as it does not provide new
information on how to improve care for these patients
post-transplantation, particularly those with HIV-HCV
co-infection who still have very poor outcomes."
The National Institutes of Health partially supported this
research. The authors reported no relevant disclosures.
SOURCE: http://bit.ly/1EOl1kY and http://bit.ly/1HxYx83
J Am Soc Nephrol 2015.
|